Study Title

The Clinical Impact and Prognostic Value of [18F] PSMA-1007 Imaging for Primary Staging of Prostate Cancer: Real-world Evidence from a Monocentric, Prospective Observational Study

Study Details

Description:

The investigators now intend to prospectively generate evidence-based data in everyday clinical practice with this so-called Real-World-Evidence (RWE) study. The planned study will enable us to analyze the diagnostic accuracy of Radelumin® in more detail under everyday conditions, whereby dedicated examinations of certain subgroups and the prospective generation of a complete, high-quality database for the future use of artificial intelligence (AI) will be made possible.

Sponsor:

Heinrich-Heine University

Contacts:

Eduards Mamlins (MD)

eduards.mamlins@med.uni-duesseldorf.de

(+49)211 8108069

Emil Novruzov (MD)

emil.novruzov@med.uni-duesseldorf.de

(+49)211 8118540

Government Study Link:

NCT06820333 - Click here to see study on

ClinicalTrials.gov

Drug Details

[18F] PSMA-1007
Isotope(s):
    FLUORINE-18
    Radioisotope: F-18
    Theranostic Role: PET Imaging
    T1/2 (Half-Life): 1.8 Hours
    Decay Mode: POSITRON β+ (96.7%), ELECTRON CAPTURE (3.3%), GAMMA 511 keV
    Energy: Eβ+ 635 keV
    Range: N/A
    Decay Daughters: O18 (Stable)
    Status: FDA Approvals: FDG (Cancer 2005): GLUDEF®, METATRACE® AXUMIN® (2016), PYLARIFY® (2023), POSLUMA® (2024)
  • FLUORINE-18
Target(s):
  • PSMA
XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468